Literature DB >> 8208392

Progressive supranuclear palsy: neuropathologic and clinical heterogeneity.

M Gearing1, D A Olson, R L Watts, S S Mirra.   

Abstract

To investigate potential heterogeneity in progressive supranuclear palsy (PSP), we examined 13 patients with neuropathologically diagnosed PSP. The clinical diagnosis of PSP was made in eight of these individuals, whereas probable AD was the primary diagnosis in the remaining five. In addition to PSP neuropathology, seven of the 13 patients (54%) showed concomitant pathologic changes of Alzheimer's disease (AD), Parkinson's disease (PD), or both disorders. These observations indicate that AD and PD changes coexist with PSP neuropathology in a substantive proportion of patients and provide further evidence of clinical and neuropathologic heterogeneity in neurodegenerative disorders. Moreover, our results suggest that PSP may be underdiagnosed and deserves more prominence in the differential diagnosis of dementing illness.

Entities:  

Mesh:

Year:  1994        PMID: 8208392     DOI: 10.1212/wnl.44.6.1015

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

Review 1.  Co-existence of Parkinson's disease and progressive supranuclear palsy: case report and a review of the literature.

Authors:  Kumar Abhinav; Laura Marsh; Barbara Crain; Stephen G Reich; Kevin Biglan
Journal:  Neurol Sci       Date:  2010-08-25       Impact factor: 3.307

2.  Concomitant pathologies among a spectrum of parkinsonian disorders.

Authors:  Brittany N Dugger; Charles H Adler; Holly A Shill; John Caviness; Sandra Jacobson; Erika Driver-Dunckley; Thomas G Beach
Journal:  Parkinsonism Relat Disord       Date:  2014-02-22       Impact factor: 4.891

Review 3.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam.

Authors:  Mark S Forman; M Luise Schmidt; Sanjay Kasturi; Daniel P Perl; Virginia M-Y Lee; John Q Trojanowski
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

5.  Alzheimer's disease in a case of cortical basal ganglionic degeneration with severe dementia.

Authors:  D A Eberhard; M B Lopes; J M Trugman; H R Brashear
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-01       Impact factor: 10.154

Review 6.  Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration.

Authors:  D W Dickson
Journal:  J Neurol       Date:  1999-09       Impact factor: 4.849

7.  Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.

Authors:  I Litvan; C A Mangone; A McKee; M Verny; A Parsa; K Jellinger; L D'Olhaberriague; K R Chaudhuri; R K Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

8.  Submandibular gland biopsy for the diagnosis of Parkinson disease.

Authors:  Thomas G Beach; Charles H Adler; Brittany N Dugger; Geidy Serrano; Jose Hidalgo; Jonette Henry-Watson; Holly A Shill; Lucia I Sue; Marwan N Sabbagh; Haruhiko Akiyama
Journal:  J Neuropathol Exp Neurol       Date:  2013-02       Impact factor: 3.685

9.  Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy.

Authors:  Adam Gerstenecker; Benjamin Mast; Kevin Duff; Tanis J Ferman; Irene Litvan
Journal:  Arch Clin Neuropsychol       Date:  2012-11-04       Impact factor: 2.813

10.  Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy.

Authors:  Dana Wagshal; Sethu Sankaranarayanan; Valerie Guss; Tracey Hall; Flora Berisha; Iryna Lobach; Anna Karydas; Lisa Voltarelli; Carole Scherling; Hilary Heuer; Maria Carmela Tartaglia; Zachary Miller; Giovanni Coppola; Michael Ahlijanian; Holly Soares; Joel H Kramer; Gil D Rabinovici; Howard J Rosen; Bruce L Miller; Jere Meredith; Adam L Boxer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-06-04       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.